Federal Register #2026-14848

Description

The National Center for Advancing Translational Sciences, part of the National Institutes of Health, is considering granting an Exclusive Patent License for inventions related to RXFP1 agonists to Modala Bio, Inc. The inventions include novel small molecule agonists targeting the relaxin receptor (RXFP1) for treating diseases such as fibrosis, certain cancers, vascular calcifications, and heart failure. These agonists offer advantages like improved bioavailability and low toxicity. Written comments or license applications must be received by August 24, 2026.

View original listing